Human lymphoid protein tyrosine phosphatases

An isolated polynucleotide which encodes a Lyp protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 2.

An isolated polynucleotide which encodes a Lyp protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 4.

An isolated polynucleotide which encodes a Lyp protein having an amino acid sequence with at least 80% overall identity, preferably at least 90% overall identity to the amino acid sequence of Table 2.

An isolated polynucleotide which encodes a Lyp protein having an amino acid sequence with at least 80% overall identity, preferably at least 90% overall identity to the amino acid sequence of Table 4.

A nucleotide sequence comprising at least 10, preferably 15 and more preferably 20 consecutive nucleotides of Sequence ID NO:1 or Sequence ID NO:3.

A substantially purified Lyp protein.

A substantially purified protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 2.

A substantially purified protein having an amino acid sequence of greater than 70% overall identity to the amino acid sequence of Table 4.

A substantially purified protein having an amino acid sequence with at least 80% overall identity, preferably at least 90% overall identity, to the amino acid sequence of Table 2.

A substantially purified protein having an amino acid sequence with at least 80% overall identity, preferably at least 90% overall identity, to the amino acid sequence of Table 4.

A peptide comprising at least 5, preferably 10, more preferably 20 consecutive amino acids of Sequence ID NO:2 or Sequence ID NO:4.

A peptide comprising at least one functional domain of a Lyp protein.

A peptide comprising at least one antigenic determinant of a Lyp protein.

An antibody which binds specifically to a Lyp protein.

A method for screening a candidate compound for ability to modulate expression of a Lyp gene comprising

• contacting a cell with a candidate compound, wherein the cell includes a regulatory region of a Lyp gene operably joined to a coding region;
• and
• detecting a change in expression of the coding region.

A non-human animal wherein a genome of said animal, or of an ancestor thereof, has been modified by a modification selected from the group consisting of:

• (a) knockout of a Lyp gene;
• and
• (b) insertion of a polynucleotide encoding a heterologous Lyp gene.

A method for treating a subject having a deficiency of Lyp activity comprising administering to the subject an effective amount of an agent selected from the group consisting of:

• (a) an isolated nucleotide sequence encoding a Lyp protein;
• (b) a substantially purified Lyp protein.

A method for modulating signalling mediated by the T cell receptor, the method comprising administering to a T cell an agent which increases Lyp phosphatase activity or increases Lyp expression in the T cell.

A method for reducing or preventing T cell activation and/or proliferation, the method comprising administering to the T cell an agent which increases Lyp phosphatase activity or increases Lyp expression in the T cell.

A method for treating a disorder which requires immunosuppression, the method comprising administering to the subject in need of treatment an immunosuppression-effective amount of an agent which increases Lyp phosphatase activity or increases Lyp expression.

A method for treating lymphoma in a subject, the method comprising administering to the subject an agent which increases Lyp phosphatase activity or increases Lyp expression in an amount effective to reduce or prevent lymphoma cell proliferation.

A method for preventing or treating a disorder characterised by an abnormality in the T cell receptor signalling pathway or the IL2-mediated signalling pathway, comprising modulating signalling by administration of an agent which increases Lyp phosphatase activity or Lyp expression.